The BMSCs in AML patients produce much lower levels of SCF, TNF-α, monocyte chemoattractant protein-1 (MCP-1), GM-CSF, and IL-6 compared to normal BMSCs from healthy controls. This evidence concerns the gene CCL2 and acute myeloid leukemia.